Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794836 | 0.77 | — | — | |
| SCHEMBL8000519 | 0.77 | — | — | |
| SCHEMBL26198968 | 0.75 | — | — | |
| SCHEMBL6636082 | 0.75 | — | — | |
| SCHEMBL18478347 | 0.75 | — | — | |
| SCHEMBL800814 | 0.72 | — | — | |
| SCHEMBL293766 | 0.72 | — | — | |
| SCHEMBL24737759 | 0.71 | KDM4E (0.46) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL27875475 | 0.71 | KDM4E (0.46) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL11686140 | 0.71 | MTNR1A (0.50) | KDM4EMAPK1HIF1AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271993-B2 | Treatment of bacterial infectious diseases | UNIVERSITY OF ZURICH (CH) | 2016-03-01 | — | — | US | disclosed |
| EP-2616079-B1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIV ZÜRICH (CH) | 2015-10-14 | — | — | EP | disclosed |
| EP-2616079-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | University of Zürich (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | ETH ZURICH (CH) | 2013-06-27 | — | — | US | disclosed |
| WO-2012034955-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | UNIVERSITY OF ZURICH (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165397-A1 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES | APRT, BPGM, TLR5 | KDM4E 4675/4885MAPK1 1278/4885HIF1A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.